What is CGEM stock price today?

CGEM (Cullinan Therapeutics Inc) stock is trading at $15.06 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CGEM stock going up or down today?

CGEM stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CGEM stock now?

The decision to buy CGEM depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CGEM a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CGEM based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CGEM stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CGEM is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CGEM's P/E ratio?

P/E ratio data for CGEM will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CGEM's market cap?

CGEM (Cullinan Therapeutics Inc) has a market capitalization of $0.89 billion, making it a small-cap stock.

What is CGEM's price to book ratio?

CGEM trades at a price-to-book (P/B) ratio of 2.18, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CGEM pay dividends?

CGEM does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CGEM's dividend yield?

CGEM does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CGEM stock a good long-term investment?

CGEM's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CGEM's revenue growth rate?

Revenue growth data for CGEM is available on our dashboard with detailed financial statement analysis.

Profitability metrics for CGEM are available on our dashboard with complete income statement analysis.

What are the risks of investing in CGEM?

Key risks for CGEM include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CGEM compare to its competitors?

Compare CGEM to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CGEM's performance and positioning.

What is CGEM's stock price target for 2026?

Our AI model provides price targets for CGEM based on fundamental analysis: Bull case $19.58 (+30%), Base case $17.32 (+15%), Bear case $13.55 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CGEM?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CGEM. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CGEM's next earnings report?

CGEM reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CGEM - Cullinan Therapeutics Inc

NYSE * Health Care * Biotechnology

$15.06

+$0.32 (+2.17%)

About Cullinan Therapeutics Inc

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM Key Statistics

Market Cap

$892.16M

P/B Ratio

2.18

EPS

$-3.36

Employees

109

How CGEM Compares to Peers

CGEM is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CGEM(This stock)	$892.16M	N/A	0%	0.0%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Cullinan Therapeutics Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: cullinantherapeutics.com
Sector: Health Care
Industry: Biotechnology

CGEM - Cullinan Therapeutics Inc

About Cullinan Therapeutics Inc

CGEM Key Statistics

How CGEM Compares to Peers

Cullinan Therapeutics Inc Company Information

CGEM Lician Score

CGEM Financial Snowflake

Upcoming Events for CGEM